|
Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis Clinical research trials and Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis. Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis clinical trial. Human subjects often receive the most effective healthcare possible for their Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis  Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis
Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis
For Condition: Juvenile Rheumatoid Arthritis
Status: Completed
Sponsor(s): Centocor ,
Synopsis: Research study to evaluate the safety and effectiveness of an investigational drug is currently being conducted in children diagnosed with polyarticular juvenile rheumatoid arthritis with active disease while receiving methotrexate therapy. Aim of the international study is to evaluate the efficacy and safety of the drug in patients with active JRA/JIA who are receiving methotrexate therapy. Study is being conducted in Belgium, Canada, Finland, France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland, United Kingdom, and USA.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Safety/Efficacy Study
Minimum Age/Maximum Age: 4 Years/18 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria To be eligible for the trial, patients must meet all of the following criteria: - Been diagnosed with juvenile rheumatoid arthritis (JRA) for at least 6 months prior to study entry. - Be at least 4 years of age, but less than 18 years of age with onset of disease before age 16. - Must be receiving a stable methotrexate (MTX) therapy at least 3 months before trial entry. If using oral corticosteroids, must have been on a stable dose for at least 4 weeks. If using NSAIDs, patients should be on a stable dose for at least 4 weeks - The patient's parent must be capable and willing of giving informed consent, and, if appropriate for the patient's age, the patient must be capable of giving assent for study participation. Exclusion Criteria Patients who meet any of the following criteria may not be enrolled in the study: - Are incapacitated, largely or wholly bedridden, or confined to a wheelchair, or have little or no ability for age-appropriate self care. - Are pregnant, nursing, or planning a pregnancy within 18 months of enrollment. - Have a rheumatic disease other than JRA or have a history of known demyelinating diseases such as multiple sclerosis. - Have been previously treated with infliximab or any other therapeutic agent targeted at reducing TNF, including, but not limited to, REMICADE, etanercept, pentoxifylline, D2E7, CDP870, or thalidomide. - Have received DMARDs other than MTX therapy within last 4 weeks - Have had a serious infection during the previous 2 months or have a history of or ongoing chronic or recurrent infectious disease. - Have a history of known infection with human immunodeficiency virus (HIV) or have a current active hepatitis B or a known history of hepatitis C infection.
Total Enrollment:
Location and Contact Information:
Children's Hospital Medical Center-Pediatric Rheumatology Collaborative Study Group
Cincinnati, Ohio, 45229
United States
Additional Information:
Study ID Numbers: CO168T32;
Study Start Date: October 2001
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036374
Other Juvenile Rheumatoid Arthritis Studies:
1. Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis
2. Infliximab to Treat Children with Juvenile Rheumatoid Arthritis
3. Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis
4. Phase I Study of High-Dose Cyclophosphamide, Anti-Thymocyte Globulin, and Total Body Irradiation With T-Cell-Depleted Autologous Bone Marrow Rescue in Patients With High-Risk Rheumatoid Arthritis
5. TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis
Related Studies:
Other Juvenile Rheumatoid Arthritis Clinical Trials
Other Ohio Clinical Trials
Other Cincinnati Clinical Trials
Study of infliximab in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis
|
|
|
|
|
|
|
|
